Celldex Therapeutics starts study of kidney disease therapy

Celldex has started a pilot study on a new treatment.
Celldex has started a pilot study on a new

This is a summary. To read the whole story subscribe to

Shares of Celldex Therapeutics continued to rise on Friday, four days after the company said it has begun a pilot study of a treatment for a rare kidney disease called dense deposit disease. Celldex said the first patient was dosed in the study of the disease, which ultimately results in kidney failure for most patients. Celldex has its operations office in Needham and also operates a manufacturing plant in Fall River, among other facilities in the Northeast.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.